



Christopher M. Parker

he/him/his
Associate

Chicago
+1 312-558-8085

Chris concentrates his practice on internal and government investigations, regulatory matters, banking litigation, and complex commercial litigation for clients in the financial services and health care industries.

Chris maintains a focus on the health care and life sciences sector. He regularly advises health care clients on regulatory matters, including those involving federal controlled substance regulations and risk management. Chris has substantial experience defending clients in connection with a wide range of issues, including the False Claims Act and related *qui tam*/whistleblower litigation, government program fraud, the Anti-Kickback Statute, health care fraud, and government contracting fraud. In addition, Chris counsels clients on the development and enhancement of compliance programs, providing guidance for achieving compliance objectives and minimizing the risk of government investigations. Chris has successfully defended financial services institutions in complex commercial litigation and government investigations, including class actions, mass tort, and contractual disputes. He is experienced in all phases of litigation, including case assessment and strategy development, briefing and arguing motions, managing all aspects of discovery in complex litigation, including defending and taking depositions, and preparing cases and witnesses for trial.

Key Matters

ANTITRUST

- Representing clients seeking antitrust approval before the Federal Trade Commission and state attorneys general
- Represented client in obtaining antitrust clearance for transaction before the U.S. Department of Justice (DOJ)

CLASS ACTIONS

- Defending global financial institution against several high-profile class actions and single-plaintiff actions
- Defended higher education institution against COVID-19 class action, resulting in dismissal at motion to dismiss stage

COMPLEX COMMERCIAL LITIGATION

- Represented large insurance company in litigation over alleged non-payment of insurance commissions, resulting in dismissal at motion to dismiss stage

GOVERNMENT AND INTERNAL INVESTIGATIONS

- Representing financial institution in investigation by Illinois Attorney General
- Representing individuals in DOJ investigations
- Representing medical device manufacturer in DOJ investigation
- Representing individuals and companies against False Claims Act allegations
- Representing individuals in high-profile higher education internal investigations

PRO BONO

- Represented client in state criminal matter resulting in all felony charges being dropped and expunged from client's record
- Successfully represented client in divorce proceedings
- Representing client seeking relief related to delay of medical treatment claims under 42 U.S.C. 1983

Recent Experience

Allscripts' Sale of EPSi to Strata Decision Technology

Recognitions

- Recognized by *Best Lawyers: Ones to Watch[®] in America* – Criminal Defense: White-Collar, 2024
 - The National Black Lawyers' (NBL) "Top 40 Under 40," 2021, 2022
 - CALI Award – Legal Writing
-

Activities

Chris actively participates in the firm's pro bono program, where he has represented defendants in criminal matters in Illinois state court, as well as clients in the Northern District of Illinois. Chris is a member of the firm's Health Care & Life Sciences Industry Group, where he leads associate engagement related to health care fraud and abuse issues and regularly publishes articles on the firm's FCA Playbook. Chris is an associate advisor to the firm's Black Lawyers Network. He is also an active member of the Chicago Bar Association.

Credentials

EDUCATION

Chris received his J.D. from The University of Chicago in 2018. He received his B.S., in Psychology and Neuroscience from The University of Maryland, College Park in 2012.

ADMISSIONS

- Illinois

Related Insights & News

- • "2023 DOJ FCA Enforcement: Expectations for Future," Bloomberg Law, Co-author, April 5, 2024
- "DOJ Further Pursues False Claims Act Violations Related to Fraudulent Paycheck Protection Program Loans," Co-author, Aug. 15, 2023
- "DOJ Continues to Crack Down on Health Care Fraud Violations, Announcing Convictions and Enforcement Activity," Co-author, Aug. 14, 2023
- "June 2023 FCA Settlement Wrap-Up: DOJ Continues to Crack Down on Health Care Fraud," Co-author, Aug. 14, 2023
- "DOJ's 2022 FCA Recoveries Announcement Reveals One of the Smallest Hauls in Recent Years, But Indicates a Different 2023 Outlook," Co-author, March 28, 2023
- "DOJ Continues Pursuit of False Claims Act Violations Related to Fraudulent Paycheck Protection Program Loans," Co-author, Feb. 28, 2023
- "NortonLifeLock Found Liable After FCA Trial, But Government Leaves Damages Money On The Table," Co-author, Feb. 27, 2023
- "DOJ Scrutiny of EHR Vendors Continues with \$45 Million Settlement For Alleged Kickbacks and False Claims," Co-author, Nov. 14, 2022
- "8th Circ. Ruling Raises Bar for Anti-Kickback FCA Claims," Law360, Co-author, Aug. 10, 2022
- "DOJ Reaches \$20 Million Agreement with BayCare Health Systems to Settle Claims of Allegedly Improper Donations to Increase Medicaid Funding," Co-author, May 9, 2022
- "DOJ Continues to Use the False Claims Act to Protect PPP Funds," Co-author, Sept. 7, 2021
- "DOJ Announces \$22 Million False Claims Act Settlement with the University of Miami for Provider-Based Rule Violations Involving Laboratory Tests," Co-author, June 17, 2021

- [“FDA Publishes Guidance on Remote Interactive Evaluations for Oversight of Drug Manufacturing and Bioresearch Monitoring Facilities During the COVID-19 Public Health Emergency,”](#) Co-author, May 26, 2021
- [“FDA Enforcement Action Against Manufacturers for REMS Non-Compliance Reflects Agency Priorities During the Pandemic,”](#) Co-author, April 16, 2021
- [“Eli Lilly Prevails in Blocking Immediate Implementation of HHS’s 340B Drug Discount Rule Involving Dispute Resolution Between Manufacturers and Covered Entities,”](#) Co-author, March 22, 2021
- [“HHS-OIG Finalizes Significant Changes to the Anti-Kickback Statute and Stark Law,”](#) Co-author, Dec. 15, 2020
- [“HHS-OIG Issues Special Fraud Alert Directed at Drug and Device Manufacturers Regarding the Fraud and Abuse Risk of HCP Speaker Programs,”](#) Co-author, Nov. 20, 2020
- [“FDA Develops Guidance for Enhancing the Diversity of Clinical Trial Populations,”](#) Co-author, Nov. 17, 2020
- [“FDA Identifies Essential Medicines, Medical Countermeasures, and Critical Inputs Required by Executive Order 13944,”](#) Co-author, Nov. 6, 2020
- [“FDA Announces Innovative Quality Management Maturity Pilot Programs for Manufacturers of Drug Products and Active Pharmaceutical Ingredients,”](#) Co-author, Oct. 21, 2020
- [“FDA Proposes Clarifying Amendments to Its Medical Product “Intended Use” Regulations,”](#) Co-author, Sept. 29, 2020
- [“FDA Provides Guidance to Manufacturers for Controlling Nitrosamine Impurities in Human Drugs,”](#) Co-author, Sept. 18, 2020
- [“New FDA Guidance Issued to Help Drug and Biologics Manufacturers Resume Normal Manufacturing Operations,”](#) Co-author, Sept. 15, 2020
- [“FDA Calls for Comments on Its Extensive Draft Guidance on Use of Patient-Reported Outcome Instruments in Medical Device Lifecycle Analysis,”](#) Co-author, Sept. 4, 2020
- [“Trump Executive Order Seeks to Beef Up Domestic Supply Chain for Medical Products,”](#) Co-author, Aug. 11, 2020
- [“Trump Administration Announces Executive Action Intended to Reshape the Economics of the Prescription Drug Distribution Chain in the United States,”](#) Co-author, Aug. 4, 2020
- [“Trump Administration Announces Executive Action Intended to Use Cross-Border Market Forces to Impact Drug Pricing in the U.S. Market,”](#) Co-author, July 28, 2020
- [“FDA Announces the Resumption of Domestic Inspections As Part of Evolving COVID-19 Pandemic Response,”](#) Co-author, July 16, 2020
- [“FDA Offers Good Manufacturing Practice Considerations to Drug/Biological Manufacturers Responding to COVID-19 Infections,”](#) Co-author, June 24, 2020
- [“FDA Issues New Temporary Policy on Prescription Drug Samples in Light of the COVID-19 Public Health Emergency,”](#) Co-author, June 16, 2020
- [“CMS Issues Regulatory Waivers Easing Restrictions on Durable Medical Equipment Suppliers and Expands Accelerated/Advanced Payment Program,”](#) Co-author, April 15, 2020
- [“CMS Issues Regulatory Waivers Easing Restrictions on HHAs and Hospice Providers in Light of COVID-19 Pandemic,”](#) Co-author, April 8, 2020

BLOG

2023 DOJ FCA Enforcement: Expectations for Future

APRIL 8, 2024

BLOG

Winston & Strawn Launches Fifth Cohort of D&I Associate Sponsorship Program

OCTOBER 19, 2023

RECOGNITIONS

Winston Attorneys Recognized in *Best Lawyers: Ones to Watch® in America 2024*

AUGUST 17, 2023

BLOG

DOJ Further Pursues False Claims Act Violations Related to Fraudulent Paycheck Protection Program Loans

AUGUST 15, 2023

BLOG

DOJ Continues to Crack Down on Health Care Fraud Violations, Announcing Convictions and Enforcement Activity

AUGUST 14, 2023

BLOG

June 2023 FCA Settlement Wrap-Up: DOJ Continues to Crack Down on Health Care Fraud

AUGUST 14, 2023

BLOG

DOJ's 2022 FCA Recoveries Announcement Reveals One of the Smallest Hauls in Recent Years, But Indicates a Different 2023 Outlook

MARCH 28, 2023

BLOG

DOJ Continues Pursuit of False Claims Act Violations Related to Fraudulent Paycheck Protection Program Loans

FEBRUARY 28, 2023

BLOG

NortonLifeLock Found Liable After FCA Trial, But Government Leaves Damages Money On The Table

FEBRUARY 27, 2023

RECOGNITIONS

Three Winston & Strawn Attorneys Selected for 2023 LCLD Fellows and Pathfinder Programs

JANUARY 31, 2023

RECOGNITIONS

Winston & Strawn Antitrust/Competition Practice Recognized in 2023 GCR 100

BLOG

DOJ Scrutiny of EHR Vendors Continues with \$45 Million Settlement For Alleged Kickbacks and False Claims

NOVEMBER 14, 2022

Capabilities

Antitrust/Competition

Commercial Litigation & Disputes

Government Investigations, Enforcement & Compliance

Government Program Fraud, False Claims Act & Qui Tam Litigation

Litigation/Trials

Antitrust Transactions

Health Care

Medical Devices